Gene: VAMP2

6844
SYB2|VAMP-2
vesicle associated membrane protein 2
protein-coding
17p13.1
Ensembl:ENSG00000220205 MIM:185881 Vega:OTTHUMG00000150254 UniprotKB:P63027
NC_000017.11
PubMed
0   ANCO-SNPs
CD|ND|AD
3   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.540e-1 (AD)  2.816e-2 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg05012902chr17:8065517VAMP24.410e-9Alcohol consumption der day27843151

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CALM30.973
SPRYD30.965
CLIP30.962
AP2M10.96
SCAMP50.959
GSK3A0.959
DNAJC50.958
ATP6V0A10.958
CALM10.955
NDRG40.953

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.717
OR4F29-0.687
TFPI2-0.405
REST-0.403
CCR2-0.392
CST7-0.377
IL18RAP-0.377
CXCR2-0.377
WWTR1-0.374
CLEC2B-0.373

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00042Botulinum Toxin Type BBiotechDrug93384-44-2Approved|InvestigationalTarget
ID Drug Name Action PubMed
C0493251,2-dithiol-3-thione"1,2-dithiol-3-thione results in increased expression of VAMP2 mRNA"19162173
C0297902,2',3',4,4',5-hexachlorobiphenyl"2,2',3',4,4',5-hexachlorobiphenyl results in decreased expression of VAMP2 mRNA"23829299
C0942102,2'-(hydroxynitrosohydrazono)bis-ethanamine"2,2'-(hydroxynitrosohydrazono)bis-ethanamine inhibits the reaction [lead acetate affects the localization of VAMP2 protein]"22265330
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in increased expression of VAMP2 mRNA"19114083
C0094072,5,2',5'-tetrachlorobiphenyl"2,5,2',5'-tetrachlorobiphenyl results in increased expression of VAMP2 mRNA"23829299
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in increased expression of VAMP2 mRNA"18648102
D000082AcetaminophenAcetaminophen affects the expression of VAMP2 mRNA17562736
D000643Ammonium ChlorideAmmonium Chloride affects the expression of VAMP2 mRNA16483693
D001152ArsenicalsArsenicals results in decreased methylation of VAMP2 promoter23315758
C024990asolectinasolectin promotes the reaction [rimabotulinumtoxinB results in increased cleavage of VAMP2 protein modified form]27032463
C547126AZM551248AZM551248 results in decreased expression of VAMP2 mRNA22323515
C030935benz(a)anthracenebenz(a)anthracene results in increased expression of VAMP2 mRNA26377693
D001564Benzo(a)pyreneBenzo(a)pyrene promotes the reaction [AHR protein binds to VAMP2 promoter]19654925
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of VAMP2 mRNA22228805
C551172bis-N,N-dimethylamino-2-(N-methylpyrrolyl)methyl cyclopentadienyl titanium (IV)"bis-N,N-dimethylamino-2-(N-methylpyrrolyl)methyl cyclopentadienyl titanium (IV) results in decreased expression of VAMP2 mRNA"20162321
C006780bisphenol Abisphenol A affects the expression of VAMP2 mRNA21786754
C006780bisphenol Abisphenol A results in increased expression of VAMP2 mRNA25181051
C006780bisphenol Abisphenol A results in increased expression of VAMP2 protein28739533
C096325botulinum toxin type Dbotulinum toxin type D results in increased cleavage of and results in increased degradation of VAMP2 protein26615023
C096325botulinum toxin type Dbotulinum toxin type D results in increased cleavage of VAMP2 protein11181932
C096325botulinum toxin type Dbotulinum toxin type D results in increased cleavage of VAMP2 protein17666428
C096321botulinum toxin type Fbotulinum toxin type F results in increased cleavage of and results in increased degradation of VAMP2 protein26615023
C488535botulinum toxin type Gbotulinum toxin type G results in increased cleavage of and results in increased degradation of VAMP2 protein26615023
C584509C646 compoundC646 compound results in decreased expression of VAMP2 mRNA26191083
D002211CapsaicinCapsaicin results in decreased expression of VAMP2 mRNA20349343
D002251Carbon TetrachlorideCarbon Tetrachloride affects the expression of VAMP2 mRNA17484886
D003024ClozapineClozapine results in increased expression of VAMP2 mRNA15860345
C018021cobaltous chloridecobaltous chloride results in decreased expression of VAMP2 mRNA19320972|1937684
C010902decabromobiphenyl etherdecabromobiphenyl ether results in decreased expression of VAMP2 mRNA28104350
C010902decabromobiphenyl etherdecabromobiphenyl ether results in decreased expression of VAMP2 protein28104350
D003840Deoxycholic Acid[gluconic acid co-treated with Deoxycholic Acid] results in increased expression of VAMP2 mRNA16556975
D003976DiazinonDiazinon results in increased methylation of VAMP2 gene22964155
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of VAMP2 mRNA21266533
D002945CisplatinCisplatin results in increased expression of VAMP2 mRNA27392435
C000944dicrotophosdicrotophos results in increased expression of VAMP2 mRNA28302478
D004041Dietary FatsDietary Fats results in increased expression of VAMP2 mRNA25016146
D000431EthanolEthanol results in increased expression of VAMP2 mRNA20655511
D004997Ethinyl EstradiolEthinyl Estradiol affects the expression of VAMP2 mRNA17555576
C069837fullerene C60fullerene C60 results in increased expression of VAMP2 mRNA19167457
C030691gluconic acid[gluconic acid co-treated with Deoxycholic Acid] results in increased expression of VAMP2 mRNA16556975
D006220HaloperidolHaloperidol results in decreased expression of VAMP2 mRNA15860345
D006220HaloperidolHaloperidol results in increased expression of VAMP2 mRNA15860345
D006834HydrazinesHydrazines results in increased expression of VAMP2 mRNA21647536
D006997Hypochlorous AcidHypochlorous Acid results in decreased expression of VAMP2 mRNA19376150
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of VAMP2 mRNA23086925
D007854LeadLead affects the expression of VAMP2 mRNA28903495
C008261lead acetate"2,2'-(hydroxynitrosohydrazono)bis-ethanamine inhibits the reaction [lead acetate affects the localization of VAMP2 protein]"22265330
C008261lead acetateBDNF protein inhibits the reaction [lead acetate results in decreased expression of VAMP2 protein]20375082
C008261lead acetatelead acetate affects the expression of VAMP2 mRNA27984133
C008261lead acetatelead acetate affects the localization of VAMP2 protein22265330
C008261lead acetatelead acetate results in decreased expression of VAMP2 protein20375082
C045463leflunomideleflunomide results in increased expression of VAMP2 mRNA28988120
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of VAMP2 mRNA"20188158
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of VAMP2 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of VAMP2 mRNA"25554681
C028007nickel monoxidenickel monoxide results in increased expression of VAMP2 mRNA19167457
D010269ParaquatParaquat results in increased expression of VAMP2 mRNA18198484
C410127PCB 180PCB 180 results in increased expression of VAMP2 mRNA23829299
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of VAMP2 mRNA19710929
C006253pirinixic acidNCF1 protein promotes the reaction [pirinixic acid results in decreased expression of VAMP2 mRNA]17950772
C006253pirinixic acidpirinixic acid results in decreased expression of VAMP2 mRNA17950772
C006253pirinixic acidPPARA protein promotes the reaction [pirinixic acid results in decreased expression of VAMP2 mRNA]17950772
D010936Plant ExtractsPlant Extracts results in decreased expression of VAMP2 mRNA23557933
D017035Pravastatin[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of VAMP2 protein26875785
C045950propiconazolepropiconazole results in decreased expression of VAMP2 mRNA21278054
C059514resveratrolresveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA]25999625
C096323rimabotulinumtoxinBrimabotulinumtoxinB results in increased cleavage of and results in increased degradation of VAMP2 protein26615023
C096323rimabotulinumtoxinBrimabotulinumtoxinB results in increased cleavage of and results in increased degradation of VAMP2 protein26615023
C096323rimabotulinumtoxinBasolectin promotes the reaction [rimabotulinumtoxinB results in increased cleavage of VAMP2 protein modified form]27032463
C096323rimabotulinumtoxinBrimabotulinumtoxinB results in increased cleavage of and results in increased degradation of VAMP2 protein26615023
C096323rimabotulinumtoxinBrimabotulinumtoxinB results in increased cleavage of VAMP2 protein17666428
C096323rimabotulinumtoxinBrimabotulinumtoxinB results in increased cleavage of VAMP2 protein modified form27032463
C096323rimabotulinumtoxinBtrimethyloxamine promotes the reaction [rimabotulinumtoxinB results in increased cleavage of VAMP2 protein modified form]27032463
D013311Streptozocinresveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA]25999625
D013311Streptozocin[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA25999625
D013629TamoxifenTamoxifen affects the expression of VAMP2 mRNA17555576
C035979tetanospasmintetanospasmin results in increased cleavage of VAMP2 protein20297730
D013744Tetanus ToxinTetanus Toxin results in increased cleavage of and results in increased degradation of VAMP2 protein26615023
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of VAMP2 mRNA22574217
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of VAMP2 mRNA21570461|2468072
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with TIPARP gene mutant form] results in decreased expression of VAMP2 mRNA25975270
D013749TetrachlorodibenzodioxinAHR protein alternative form affects the reaction [Tetrachlorodibenzodioxin results in decreased expression of VAMP2 mRNA]21215274
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of VAMP2 mRNA21215274
D013853ThioacetamideThioacetamide results in decreased expression of VAMP2 mRNA23411599
D024505TocopherolsTocopherols results in increased expression of VAMP2 mRNA17654050
C005855trimethyloxaminetrimethyloxamine promotes the reaction [rimabotulinumtoxinB results in increased cleavage of VAMP2 protein modified form]27032463
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of VAMP2 mRNA"26743178
D014520UrethaneUrethane results in increased expression of VAMP2 mRNA28818685
C025643vinclozolinvinclozolin results in decreased expression of VAMP2 mRNA20566332
D014750VincristineVincristine results in decreased expression of VAMP2 mRNA23649840
D009536Niacinamideresveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA]25999625
D009536Niacinamide[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA25999625
C088658zoledronic acidzoledronic acid results in increased expression of VAMP2 protein28871336

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000149SNARE binding-ISS-  
GO:0005515protein binding-IPI9920726  10481273  17196367  17313651  19478182  19543288  
22118466  22172278  25416956  
GO:0005516calmodulin binding-ISS-  
GO:0005543phospholipid binding-ISS-  
GO:0017075syntaxin-1 binding-ISS-  
GO:0019905syntaxin binding-IBA21873635  
GO:0019905syntaxin binding-IPI12855681  
GO:0019905syntaxin binding-ISS-  
GO:0043621protein self-association-TAS15217342  
GO:0048306calcium-dependent protein binding-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006887exocytosis-TAS10099709  
GO:0009749response to glucose-ISS-  
GO:0014047glutamate secretion-TAS-  
GO:0015031protein transport-ISS-  
GO:0016079synaptic vesicle exocytosis-ISS-  
GO:0016079synaptic vesicle exocytosis-TAS15217342  
GO:0016192vesicle-mediated transport-ISS-  
GO:0017156calcium ion regulated exocytosis-ISS-  
GO:0017157regulation of exocytosis-ISS-  
GO:0032869cellular response to insulin stimulus-ISS-  
GO:0043001Golgi to plasma membrane protein transport-ISS-  
GO:0043308eosinophil degranulation-IMP16677249  
GO:0043312neutrophil degranulationNOTIMP16677249  
GO:0043320natural killer cell degranulationNOTIMP18042464  
GO:0060291long-term synaptic potentiation-ISS-  
GO:0060627regulation of vesicle-mediated transport-ISS-  
GO:0061024membrane organization-TAS-  
GO:0061025membrane fusion-ISS-  
GO:0065003protein-containing complex assembly-ISS-  
GO:0070254mucus secretionNOTIMP22144578  
GO:0090316positive regulation of intracellular protein transport-ISS-  
GO:1902259regulation of delayed rectifier potassium channel activity-ISS-  
GO:1903593regulation of histamine secretion by mast cellNOTIMP18253931  
GO ID GO Term Qualifier Evidence PubMed
GO:0005802trans-Golgi network-ISS-  
GO:0005829cytosol-TAS-  
GO:0005886plasma membrane-ISS-  
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-TAS1976629  
GO:0008021synaptic vesicle-ISS-  
GO:0008021synaptic vesicle-TAS10099709  
GO:0008076voltage-gated potassium channel complexcolocalizes_withISS-  
GO:0016020membrane-IDA16677249  22375059  
GO:0030054cell junction-IEA-  
GO:0030136clathrin-coated vesicle-IDA19478182  
GO:0030141secretory granule-ISS-  
GO:0030665clathrin-coated vesicle membrane-TAS-  
GO:0030667secretory granule membraneNOTIDA16677249  
GO:0030667secretory granule membrane-TAS-  
GO:0030672synaptic vesicle membrane-ISS-  
GO:0030672synaptic vesicle membrane-TAS-  
GO:0031201SNARE complex-IDA12130530  12730201  19546860  
GO:0031201SNARE complex-TAS10099709  
GO:0031410cytoplasmic vesicle-ISS-  
GO:0031982vesicle-IDA17313651  
GO:0042589zymogen granule membrane-ISS-  
GO:0043005neuron projection-ISS-  
GO:0043231intracellular membrane-bounded organelle-ISS-  
GO:0044306neuron projection terminus-ISS-  
GO:0045202synapse-ISS-  
GO:0048471perinuclear region of cytoplasm-ISS-  
GO:0060203clathrin-sculpted glutamate transport vesicle membrane-TAS-  
GO:0061202clathrin-sculpted gamma-aminobutyric acid transport vesicle membrane-TAS-  
GO:0070032synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex-ISS-  
GO:0070033synaptobrevin 2-SNAP-25-syntaxin-1a-complexin II complex-ISS-  
GO:0070044synaptobrevin 2-SNAP-25-syntaxin-1a complex-ISS-  
GO:0070083clathrin-sculpted monoamine transport vesicle membrane-TAS-  
KEGG ID KEGG Term
hsa04130SNARE interactions in vesicular transport
hsa04962Vasopressin-regulated water reabsorption
hsa04970Salivary secretion
Reactome ID Reactome Term Evidence
R-HSA-112310Neurotransmitter release cycleTAS
R-HSA-112315Transmission across Chemical SynapsesTAS
R-HSA-112316Neuronal SystemTAS
R-HSA-1280215Cytokine Signaling in Immune systemTAS
R-HSA-1430728MetabolismIEA
R-HSA-1445148Translocation of GLUT4 to the plasma membraneIEA
R-HSA-163685Integration of energy metabolismIEA
R-HSA-1643685DiseaseTAS
R-HSA-168256Immune SystemTAS
R-HSA-168799Neurotoxicity of clostridium toxinsTAS
R-HSA-181429Serotonin Neurotransmitter Release CycleTAS
R-HSA-181430Norepinephrine Neurotransmitter Release CycleTAS
R-HSA-199991Membrane TraffickingTAS
R-HSA-199991Membrane TraffickingIEA
R-HSA-199992trans-Golgi Network Vesicle BuddingTAS
R-HSA-210500Glutamate Neurotransmitter Release CycleTAS
R-HSA-212676Dopamine Neurotransmitter Release CycleTAS
R-HSA-264642Acetylcholine Neurotransmitter Release CycleTAS
R-HSA-264876Insulin processingIEA
R-HSA-2980736Peptide hormone metabolismIEA
R-HSA-392499Metabolism of proteinsIEA
R-HSA-421837Clathrin derived vesicle buddingTAS
R-HSA-422356Regulation of insulin secretionIEA
R-HSA-432720Lysosome Vesicle BiogenesisTAS
R-HSA-432722Golgi Associated Vesicle BiogenesisTAS
R-HSA-449147Signaling by InterleukinsTAS
R-HSA-449836Other interleukin signalingTAS
R-HSA-5250955Toxicity of botulinum toxin type D (BoNT/D)TAS
R-HSA-5250958Toxicity of botulinum toxin type B (BoNT/B)TAS
R-HSA-5250981Toxicity of botulinum toxin type F (BoNT/F)TAS
R-HSA-5250982Toxicity of tetanus toxin (TeNT)TAS
R-HSA-5250989Toxicity of botulinum toxin type G (BoNT/G)TAS
R-HSA-5339562Uptake and actions of bacterial toxinsTAS
R-HSA-5653656Vesicle-mediated transportTAS
R-HSA-5653656Vesicle-mediated transportIEA
R-HSA-5663205Infectious diseaseTAS
R-HSA-8856825Cargo recognition for clathrin-mediated endocytosisTAS
R-HSA-8856828Clathrin-mediated endocytosisTAS
R-HSA-888590GABA synthesis, release, reuptake and degradationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
21426264Candidate pathway association study in cocaine dependence: the control of neurotransmitter release. (2012 Feb)Fernandez-Castillo NWorld J Biol Psychiatry
15846778Transcriptome analysis of frontal cortex in alcohol-preferring and nonpreferring rats. (2005 May 15)Worst TJJ Neurosci Res
26200269Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. (2015 Aug)Shim HSJ Thorac Oncol